drug
(umeclidinium bromide + vilanterol trifenatate)
Marketedupdated 3mo agoby GlaxoSmithKline LLC
Approvedcommunity read0 votes
indications
investigational
COPD
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 14, 2027
323 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Nov 29, 2030method-of-use (U-3203)US 110902944.3y
- Nov 29, 2030formulationUS 123969864.3y
- Nov 29, 2030formulationUS 97507264.3y
- Dec 18, 2027compositionUS 74888271.4y
- Dec 14, 2027patentUS 8511304*PED1.4y
- Jun 14, 2027formulationUS 8511304323d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 46m ago
Found something off?
comments(0)
5-min edit window · permanent after that